News and updates

New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment

December 7, 2018

PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment BluePrint reclassified 85 percent of tumors identified as HER2-amplified by IHC/FISH to non-HER2 molecular subtype and clarified the biology of HER2 “equivocal” breast cancer 46 percent of women under 50 years of age…

Read more

New Research to be Presented at SABCS 2018 Reinforces MammaPrint and BluePrint Testing to Guide Breast Cancer Treatment Management Decisions

December 5, 2018

PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium IRVINE, CA, AMSTERDAM, NETHERLANDS – 28 November 2018 – Agendia, Inc., a world leader in precision oncology, will present new data reinforcing the…

Read more

Oncology Consultants Joins Agendia’s FLEX Big Data Registry Study

December 4, 2018

PRESS RELEASE Oncology Consultants Join Agendia’s FLEX Big DataRegistry Study, Helping to Build a Unique Resource for Breast Cancer Research All Oncology Consultants practices participate in the initiative, matching full genome profiles with complete clinical data to create a comprehensive patient database IRVINE, CALIF., U.S., HOUSTON, TEXAS, U.S., AMSTERDAM, NETHERLANDS – 4 December 2018 –…

Read more

Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients

November 14, 2018

 PRESS RELEASE Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients New data from the trial shows that a subgroup of “ultra-high risk” patients identified by MammaPrint respond better to certain targeted therapies and treatment combinations In a separate…

Read more